ArticleAME case reports2023
Lifting agent granuloma presenting as a colonic mass mimicking cancer: a report of three cases.
Article in AME case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- A case of recurrent early gastric cancer with a giant injection-related granuloma after endoscopic submucosal dissection resulting in non-curative resection.Clinical journal of gastroenterology · 2026Article
- Submucosal injection-related foreign body reaction complicating endoscopic submucosal dissection: this time, it is not the usual suspect.iGIE : innovation, investigation and insights · 2026Article
- Sodium Alginate-Based Submucosal Lifting Hydrogel for Endoscopic Mucosal Resection and Endoscopic Submucosal Dissection.Advanced healthcare materials · 2026Article
- Unexpected Discovery at Resection Site: Plasmablastic Lymphoma After Polypectomy.ACG case reports journal · 2025Article
- The demise of ORISE, a submucosal lifting agent for endoscopic resection.AME case reports · 2023Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Food and Drug Administration (FDA)-approved submucosal injection of lifting agents such as ORISE Cases Description: Three cases were identified in a six-month span based on the histological presence of a lifting agent granuloma in a colonic/colorectal resection specimen with associated clinical, imaging and gross concern for invasive malignancy. Each case resulted in an escalation of clinical and surgical management due to the suspicion of an unresectable neoplastic process that was at least partially involved by an exuberant granulomatous reaction due to the utilization of a lifting agent. Colonic transmural involvement and sub-serosal vascular infiltration by the granulomas are described. Conclusions: Lifting agent granulomas have become a routine endoscopic technique to help achieve full resection of flat/sessile colorectal polyps and early-stage cancers. This report confirms that these granulomas exhibit colonic transmural involvement. Sub-serosal blood vessel involvement is reported for the first time. It is important to recognize the unique characteristics of these new synthetic lifting agents. Their propensity to develop a mass-forming granulomatous reaction has the potential to mimic invasive adenocarcinoma clinically, radiologically and pathologically. This can significantly impact patient care and management both clinically and surgically.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.